Month: September 2022

30 September 2022, Nicosia, Cyprus | Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (EPH), a real estate investment company, today announces its interim unaudited results for the first half of 2022. BUSINESS HIGHLIGHTS FIRST HALF YEAR 2022In February 2022, EPH European Property Holdings PLC (the “Company” or “EPH”) relocated to Cyprus, a member of the European Union and euro zone. Furthermore, EPH has changed its functional currency and presentation currency of EPH Group’s financial statements from US$ to EUR as of 1 January 2022. This takes into account the significant expansion of EPH’s European real estate portfolio and the strategy of the Company to focus its investments on major European cities. In addition, the change increases transparency and allows the Company to better reflect the performance...

PRESS RELEASE Regulated Information Paris, 30 September 2022   Availability of the Half Year Financial Report of Societe Generale SFH   Societe Generale SFH (“Société de Financement de l’Habitat”, Home Loans SFH) hereby informs the public that the Half Year Financial Report for the period ended 30 June 2022 has been filed with the French Financial Markets Authority (AMF) on 30 September 2022.   This document, available in French only, is made available to the public, free of charge, in accordance with the conditions provided for by the regulations in force and may be consulted in the “Societe Generale Home Loans SFH / Regulated information » section of the Societe Generale group’s website (https://investors.societegenerale.com/en/financial-and-non-financial-information/debt-investors) and on the AMF’s website.     Press contact : Jean-Baptiste...

PRESS RELEASE Regulated Information Paris, 30 September 2022   Availability of the Half Year Financial Report of Societe Generale SCF   Societe Generale SCF (“Société de Crédit Foncier”, Public Sector Loans) hereby informs the public that the Half Year Financial Report for the period ended 30 June 2022, has been filed with the French Financial Markets Authority (AMF) on 30 September 2022.   This document, available in French only, is made available to the public, free of charge, in accordance with the conditions provided for by the regulations in force and may be consulted in the “Societe Generale Public Sector Loans SCF / Regulated information » section of the Societe Generale group’s website (https://investors.societegenerale.com/en/financial-and-non-financial-information/debt-investors) and on the AMF’s website.   Press contact : Jean-Baptiste...

A first half of 2022, in development,primarily dedicated to preparing for tomorrow’s success Dardilly, 30 September 2022 – 6.30 pmConsolidated revenue increased by 22% to €8.5 million The first commands related to the ISS Spotter and Countbot systems are effective The program of strong reduction of operating expenses in France (DDSA branch) is completed and will have effect from the2nd half of the year The success of the €3 million fundraising operation sustains the group’s cash flowIFRS Standards (in K€) 1is sem. 2022 1is as. 2021 FY 2021TURNOVER 8 530 6 987 15 865Other products of the activity (393) 582 1 420Purchases and inventory changes 3 861 3 533 7 164Personnel costs 8 694 6 994 15 718Other operating income/expenses. Current 240 268 534EBITDA (4 658) (3 226) (6 131)Net depreciation allowances 1...

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2022 AND THE KEY EVENTS OF THE PERIODClinical developmentAuthorization by Health Canada in February 2022 to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy and formal start of the review in May 2022. Health Canada has a target of 200 calendar days maximum to review the application Filing for conditional Marketing Authorization to the European Medicines Agency (EMA) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) and formal start of the review in August 2022 Launch of a confirmatory Phase 3 study with masitinib in progressive forms of multiple sclerosis Positive recommendation of the Data and Safety Monitoring Board...

2022 FIRST-HALF EARNINGS: SUSTAINED GROWTH IN PROFITABILITY, WITH AN EBITDA MARGIN OF 17.5%Net sales growth of +17.9% to €89.1m Gross margin up +12.6% to €72.0m +€3.3m improvement in EBITDA to €12.6m ‏Consolidated net income up +€2m to €6.9mParis, 30 September 2022 (6:00pm) – The DÉKUPLE Group, a cross-channel data marketing expert, is reporting its earnings for the first half of 2022. Bertrand Laurioz, DÉKUPLE Group Chairman and CEO: “Driven by the alignment of its solutions with the digitalization and datafication challenges facing businesses, DÉKUPLE recorded +18% net sales growth during the first half of 2022, achieving a rate of development in line with our Ambition 2025 strategic plan aiming to become a European leader for data marketing. In a tense geopolitical and economic environment, this robust development is supported...

         Proactis SA Announces Financial Information for the year ended 31 July 2022 Paris – September 30, 2022 – Proactis SA (Euronext: PROAC), a leading provider of comprehensive spend management and business process collaboration solutions, today announces financial information for the year ended 31 July 2022, in accordance with the “European Transparency Obligations Directive” financial disclosure requirements. Financial datain € million     Year ended 31 July 2022   Year ended 31 July 2021   % Change2022/ 2021(*)               Consolidated Operational Revenue (***)     9.8   11.2   -12%SaaS (**)     7.9   9.9   -20%Services     1.9   1.3   48%               Management fees (****)     4.6   3.8   18%               Consolidated Revenue     14.4   15.0   -5%(unaudited Figures)              (*) Percentages...